PMID- 32691892
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 76
IP  - 1
DP  - 2021 Jan
TI  - Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A 
      systematic review for the EAACI biologicals guidelines.
PG  - 45-58
LID - 10.1111/all.14510 [doi]
AB  - This systematic review evaluates the efficacy, safety and economic impact of 
      dupilumab compared to standard of care for uncontrolled moderate-to-severe atopic 
      dermatitis (AD). Pubmed, EMBASE and Cochrane Library were searched for RCTs and 
      health economic evaluations. Critical and important AD-related outcomes were 
      considered. The risk of bias and the certainty of the evidence were assessed 
      using GRADE. Seven RCTs including 1845 subjects >12 years treated with dupilumab 
      16 to 52 weeks were evaluated. For adults, there is high certainty that dupilumab 
      decreases SCORAD (MD -30,72; 95% CI -34,65% to -26,79%) and EASI-75 (RR 3.09; 95% 
      CI 2.45 to 3.89), pruritus (RR 2.96; 95% CI 2.37 to 3.70), rescue medication (RR 
      3.46; 95% CI 2.79 to 4.30), sleep disturbance (MD -7.29; 95% CI -8.23 to -6.35) 
      and anxiety/depression (MD -3.08; 95% CI -4.41 to -1.75) and improves quality of 
      life (MD -4.80; 95% CI -5.55 to -4.06). The efficacy for adolescents is similar. 
      Dupilumab-related adverse events (AEs) slightly increase (low certainty). The 
      evidence for dupilumab-related serious AE is uncertain. The incremental 
      cost-effectiveness ratio ranged from 28 500  pound (low certainty) to 124 541 US$ 
      (moderate certainty). More data on long-term safety are needed both for children 
      and for adults, together with more efficacy data in the paediatric population. 
      Registration: PROSPERO (CRD42020153645).
CI  - (c) 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
FAU - Agache, Ioana
AU  - Agache I
AUID- ORCID: 0000-0001-7994-364X
AD  - Faculty of Medicine, Transylvania University, Brasov, Romania.
FAU - Song, Yang
AU  - Song Y
AD  - Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane 
      Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
FAU - Posso, Margarita
AU  - Posso M
AD  - Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane 
      Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
AD  - Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical 
      Research Institute), Barcelona, Spain.
FAU - Alonso-Coello, Pablo
AU  - Alonso-Coello P
AD  - Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane 
      Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
FAU - Rocha, Claudio
AU  - Rocha C
AD  - Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane 
      Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
FAU - Sola, Ivan
AU  - Sola I
AD  - Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane 
      Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
FAU - Beltran, Jessica
AU  - Beltran J
AD  - Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane 
      Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
FAU - Akdis, Cezmi A
AU  - Akdis CA
AUID- ORCID: 0000-0001-8020-019X
AD  - Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 
      Davos, Switzerland.
AD  - Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.
FAU - Akdis, Mubeccel
AU  - Akdis M
AUID- ORCID: 0000-0003-0554-9943
AD  - Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, 
      Davos, Switzerland.
AD  - Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland.
FAU - Brockow, Knut
AU  - Brockow K
AUID- ORCID: 0000-0002-2775-3681
AD  - Department of Dermatology and Allergology Biederstein, Technical University of 
      Munich, Munich, Germany.
FAU - Chivato, Tomas
AU  - Chivato T
AD  - School of Medicine, University CEU San Pablo, Madrid, Spain.
FAU - Del Giacco, Stefano
AU  - Del Giacco S
AUID- ORCID: 0000-0002-4517-1749
AD  - Department of Medical Sciences and Public Health, University of Cagliari, 
      Cagliari, Italy.
FAU - Eiwegger, Thomas
AU  - Eiwegger T
AUID- ORCID: 0000-0002-2914-7829
AD  - Translational Medicine Program, Research Institute, Hospital for Sick Children, 
      Toronto, ON, Canada.
AD  - Department of Immunology, University of Toronto, Toronto, ON, Canada.
AD  - Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The 
      Hospital for Sick Children, Departments of Paediatrics and Immunology, University 
      of Toronto, Toronto, Canada.
FAU - Eyerich, Kilian
AU  - Eyerich K
AUID- ORCID: 0000-0003-0094-2674
AD  - Department of Dermatology and Allergy Biederstein, Technical University of 
      Munich, Munich, Germany.
FAU - Gimenez-Arnau, Ana
AU  - Gimenez-Arnau A
AUID- ORCID: 0000-0001-5434-7753
AD  - Department of Dermatology, Hospital del Mar- Institut Mar d'Investigacions 
      Mediques, Universitat Autonoma de Barcelona, Bellaterra, Spain.
FAU - Gutermuth, Jan
AU  - Gutermuth J
AD  - Department of Dermatology, Universitair Ziekenhuis Brussel, Vrije Universiteit 
      Brussel (VUB), Brussels, Belgium.
FAU - Guttman-Yassky, Emma
AU  - Guttman-Yassky E
AUID- ORCID: 0000-0002-9363-324X
AD  - Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Maurer, Marcus
AU  - Maurer M
AUID- ORCID: 0000-0002-4121-481X
AD  - Dermatological Allergology, Allergie-Centrum-Charite, Department of Dermatology 
      and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany.
FAU - Ogg, Graham
AU  - Ogg G
AD  - MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford 
      NIHR Biomedical Research Centre, Radcliffe Department of Medicine, University of 
      Oxford, Oxford, UK.
FAU - Ong, Peck Y
AU  - Ong PY
AD  - Division of Clinical Immunology & Allergy, Children's Hospital Los Angeles, Keck 
      School of Medicine, University of Southern California, Los Angeles, CA, USA.
FAU - O'Mahony, Liam
AU  - O'Mahony L
AUID- ORCID: 0000-0003-4705-3583
AD  - Departments of Medicine and Microbiology, APC Microbiome Ireland, University 
      College Cork, Cork, Ireland.
FAU - Schwarze, Jurgen
AU  - Schwarze J
AD  - Centre for Inflammation Research, Child Life and Health, The University of 
      Edinburgh, Edinburgh, UK.
FAU - Werfel, Thomas
AU  - Werfel T
AD  - Division of Immunodermatology and Allergy Research, Department of Dermatology and 
      Allergy, Hannover Medical School, Hannover, Germany.
FAU - Canelo-Aybar, Carlos
AU  - Canelo-Aybar C
AD  - Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane 
      Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
FAU - Palomares, Oscar
AU  - Palomares O
AUID- ORCID: 0000-0003-4516-0369
AD  - Department of Biochemistry and Molecular Biology, Chemistry School, Complutense 
      University of Madrid, Madrid, Spain.
FAU - Jutel, Marek
AU  - Jutel M
AD  - Department of Clinical Immunology, Department of Clinical Immunology, University 
      of Wroclaw, Wroclaw, Poland.
AD  - ALL-MED" Medical Research Institute, Wroclaw, Poland.
LA  - eng
GR  - G116/150/MRC_/Medical Research Council/United Kingdom
GR  - MC_U137881017/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_00008/5/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12010/5/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Systematic Review
DEP - 20201004
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biological Products)
RN  - 420K487FSG (dupilumab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized
MH  - *Biological Products
MH  - Child
MH  - *Dermatitis, Atopic/drug therapy
MH  - Humans
MH  - Quality of Life
OTO - NOTNLM
OT  - EASI
OT  - SCORAD
OT  - atopic dermatitis
OT  - cost-effectiveness
OT  - dupilumab
EDAT- 2020/07/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/08 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/07/22 06:00 [entrez]
AID - 10.1111/all.14510 [doi]
PST - ppublish
SO  - Allergy. 2021 Jan;76(1):45-58. doi: 10.1111/all.14510. Epub 2020 Oct 4.